secwatch.observer — SEC 8-K summary
======================================

Issuer:     Virpax Pharmaceuticals, Inc. (—)
CIK:        0001708331
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001213900-23-093903
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Virpax appoints Gerald Bruce as CEO with $500K base salary and severance provisions
--------------------------------------------------------------------------------

- Gerald Bruce appointed CEO of Virpax Pharmaceuticals, employment agreement dated December 6, 2023.
- Annual base salary of $500,000; eligible for annual bonus up to 50% of base salary, based on Board-determined metrics.
- Severance without cause or for good reason: 12 months base salary, medical premium reimbursement, and option vesting acceleration for 12 months.
- Change in control severance: lump sum of 2x base salary plus 2x average bonus, with full equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023093903/0001213900-23-093903-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708331/000121390023093903/ea189648-8k_virpaxpharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-093903

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer